Semapimod

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Semapimod (CNI 1493;AXD-455) 是一种四价脒腙，作为细胞因子诱导的精氨酸转运和 NO 产生的选择性抑制剂，抑制 TLR4 信号传导 (IC50=0.3 uM)。

Semapimod (CNI 1493;AXD-455) is a tetravalent guanylhydrazone that acts as a selective inhibitor of cytokine-inducible arginine transport and NO production, inhibits TLR4 signaling (IC50=0.3 uM) by targeting the TLR chaperone gp96; does not inhibit EDRF activity, inhibits nitric oxide synthesis by inflammatory macrophages; prevents the development of carrageenan-induced footpad inflammation, and conferred protection against lethal LPS challenge in mice.Irritable Bowel Syndrome Phase 2 Clinical.

——

Animal Model:Male OZ rats Dosage:5 mg/kg Administration:I.p; daily for 2 weeks Result:Restored endothelium-dependent vasorelaxation in OZ rats.Animal Model:C57Bl/6 mice (GL261 cells were orthotopically implanted) Dosage:6 mg/kg/day Administration:Intracranially for 1 week, delivered via an osmotic pump Result:Inhibited tumor cell invasion by more than 75%.

CNI 1493 | AXD-455

Immunology/Inflammation

TLR

TLR

Other Indications

Irritable Bowel Syndrome

352513-83-8

744.914

C34H52N18O2

>98% (HPLC)

——

CC(=NN=C(N)N)C1=CC(=CC(=C1)NC(=O)CCCCCCCCC(=O)NC2=CC(=CC(=C2)C(=NN=C(N)N)C)C(=NN=C(N)N)C)C(=NN=C(N)N)C

N1,N10-bis(3-(1-(2-carbamimidoylhydrazono)ethyl)-5-(1-(2-carbamimidoylhydrazono)ethyl)phenyl)decanediamide

(-20℃)

With Ice Pack

≥ 2 years